Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Platform
  • Pipeline
  • Patients
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
    • Job Openings
  • Contact
Nov 02, 2021 7:00am EDT

Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Oct 26, 2021 8:00am EDT

Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021

Oct 06, 2021 8:00am EDT

Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer

Sep 09, 2021 8:00am EDT

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 24, 2021 9:00am EDT

Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

Aug 04, 2021 7:00am EDT

Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Aug 03, 2021 8:00am EDT

Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team

Jul 28, 2021 8:00am EDT

Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021

Jun 25, 2021 7:00am EDT

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

Jun 24, 2021 8:00am EDT

Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …25
  • Next
RSS
© 2023 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences